MX2023012875A - Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. - Google Patents
Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.Info
- Publication number
- MX2023012875A MX2023012875A MX2023012875A MX2023012875A MX2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A
- Authority
- MX
- Mexico
- Prior art keywords
- metabolic disease
- hfpef
- oxadiazol
- thiazol
- fluoroalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 6
- 208000016097 disease of metabolism Diseases 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 title abstract 3
- 102100022537 Histone deacetylase 6 Human genes 0.000 abstract 4
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 abstract 4
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 abstract 4
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente descripción se proporcionan métodos para tratar o prevenir una enfermedad metabólica con un inhibidor de la HDAC6. También se proporcionan en la presente descripción métodos para tratar o prevenir la insuficiencia cardíaca con fracción de eyección preservada con un inhibidor de la HDAC6. Una variedad de inhibidores de la HDAC6 se describe en la presente descripción para usar en el tratamiento o la prevención de una enfermedad metabólica o insuficiencia cardíaca con fracción de eyección conservada. En un aspecto, se describen en la presente descripción métodos para tratar a un paciente humano mediante la administración por vía oral de un inhibidor de la HDAC6, tal como un inhibidor de Fórmula (I) 0 Fórmula (II).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163183914P | 2021-05-04 | 2021-05-04 | |
US202163210690P | 2021-06-15 | 2021-06-15 | |
US202163210676P | 2021-06-15 | 2021-06-15 | |
PCT/US2022/027725 WO2022235842A1 (en) | 2021-05-04 | 2022-05-04 | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023012875A true MX2023012875A (es) | 2024-01-12 |
Family
ID=82100364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023012875A MX2023012875A (es) | 2021-05-04 | 2022-05-04 | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230381148A1 (es) |
EP (1) | EP4333841A1 (es) |
JP (1) | JP2024519499A (es) |
KR (1) | KR20240016950A (es) |
AU (1) | AU2022270657A1 (es) |
CA (1) | CA3216768A1 (es) |
IL (1) | IL308152A (es) |
MX (1) | MX2023012875A (es) |
TW (1) | TW202308619A (es) |
WO (1) | WO2022235842A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050176686A1 (en) | 2002-07-23 | 2005-08-11 | 4Sc Ag | Novel compounds as histone deacetylase inhibitors |
US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
WO2008143647A2 (en) | 2006-11-29 | 2008-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating viral infection |
US20080207704A1 (en) * | 2007-02-27 | 2008-08-28 | The Green Cross Corporation | Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists |
JP2010540630A (ja) | 2007-10-04 | 2010-12-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのn−ヒドロキシ−ナフタレンジカルボキサミド及びn−ヒドロキシ−ビフェニル−ジカルボキサミド化合物 |
KR20100095430A (ko) | 2007-11-02 | 2010-08-30 | 메틸진 인크. | 히스톤 탈아세틸화효소의 저해물질 |
US8217076B2 (en) | 2008-07-17 | 2012-07-10 | Colorado State University Research Foundation | Method for preparing largazole analogs and uses thereof |
CA2731730C (en) | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
AU2009303499A1 (en) | 2008-10-14 | 2010-04-22 | Oregon Health & Science University | Methods for the selection of therapeutic treatments for cancer |
US9096518B2 (en) | 2009-06-22 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US8624040B2 (en) | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
EP2490766A1 (en) | 2009-10-21 | 2012-08-29 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents |
WO2011106627A1 (en) | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2011146591A1 (en) | 2010-05-19 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
AU2011255281A1 (en) | 2010-05-21 | 2013-01-10 | Sloan-Kettering Institute For Cancer Research | Selective HDAC inhibitors |
WO2012012320A1 (en) | 2010-07-19 | 2012-01-26 | Millenium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US20120015943A1 (en) | 2010-07-19 | 2012-01-19 | Millennium Pharmacuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2012018499A2 (en) * | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
WO2012027564A1 (en) | 2010-08-26 | 2012-03-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
CA2812855C (en) | 2010-10-08 | 2017-12-19 | Vib Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US9249087B2 (en) | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
GB201110546D0 (en) | 2011-06-22 | 2011-08-03 | Imp Innovations Ltd | Compositions |
US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
JP5966014B2 (ja) | 2011-11-28 | 2016-08-10 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 |
EP2785720B1 (en) | 2011-11-29 | 2017-08-09 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
US9409858B2 (en) | 2012-03-07 | 2016-08-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
WO2013163455A2 (en) | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | A drug screening platform for rett syndrome |
JP2015533173A (ja) | 2012-10-12 | 2015-11-19 | トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | タンパク質脱アセチル化酵素阻害剤としてのピリミジンヒドロキシアミド化合物およびその使用方法 |
KR102168088B1 (ko) | 2013-03-14 | 2020-10-20 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법 |
EP2976344B1 (en) | 2013-03-21 | 2018-05-16 | Universiteit Gent | Hdac6 inhibitors and uses thereof |
GB201306339D0 (en) | 2013-04-08 | 2013-05-22 | Isis Innovation | Biomarkers for prognosis |
JP2016523236A (ja) | 2013-06-03 | 2016-08-08 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 多発性骨髄腫におけるヒストン脱アセチル化酵素(hdac)バイオマーカー |
US9751832B2 (en) | 2013-07-30 | 2017-09-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
WO2015042418A1 (en) | 2013-09-20 | 2015-03-26 | Acetylon Pharmaceuticals, Inc. | Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor |
EP3054939A4 (en) | 2013-10-11 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
WO2015061684A1 (en) | 2013-10-24 | 2015-04-30 | Mayo Foundation For Medical Education And Research | Treatment of polycystic diseases with an hdac6 inhibitor |
CA2929646A1 (en) | 2013-11-05 | 2015-05-14 | C & C Biopharma, Llc | Treatment of cardiac remodeling and other heart conditions |
ES2936812T3 (es) | 2013-12-20 | 2023-03-22 | Acetylon Pharmaceuticals Inc | Biomarcadores de histona desacetilasa 6 (HDAC6) en mieloma múltiple |
US9890136B2 (en) | 2013-12-23 | 2018-02-13 | The Trustees Of Columbia University In The City Of New York Memorial Sloan-Kettering Cancer Center | Selective HDAC6 inhibitors |
JP6392888B2 (ja) | 2014-03-12 | 2018-09-19 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素6阻害剤としての新規化合物およびこれを含む薬剤学的組成物 |
US20170173083A1 (en) | 2014-03-26 | 2017-06-22 | The Brigham And Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
US10016421B2 (en) | 2014-04-05 | 2018-07-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination |
US9987258B2 (en) | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
WO2015184279A1 (en) | 2014-05-30 | 2015-12-03 | The Johns Hopkins University | Compositions and methods for treating kabuki syndrome and related disorders |
WO2016020369A1 (en) | 2014-08-04 | 2016-02-11 | Universität Regensburg | Novel hdac6 inhibitors and their uses |
CN105801464B (zh) | 2014-12-29 | 2019-05-28 | 成都先导药物开发有限公司 | 吡咯酰胺类化合物及其制备方法与用途 |
US9993459B2 (en) | 2015-01-08 | 2018-06-12 | Universiteit Gent | Selective HDAC6 inhibitors and uses thereof |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
CA2975605C (en) | 2015-02-02 | 2023-12-12 | Forma Therapeutics, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
AU2016299485B2 (en) | 2015-07-27 | 2019-02-07 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
JP6560436B2 (ja) | 2015-07-27 | 2019-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾールスルホンアミド誘導体化合物及びこれを含有する薬剤学的組成物 |
US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
PL3362445T3 (pl) | 2015-10-12 | 2023-08-07 | Chong Kun Dang Pharmaceutical Corp. | Związki będące pochodnymi oksadiazoloamin jako inhibitor deacetylazy histonowej 6 oraz kompozycja farmaceutyczna obejmujące takie związki |
EP3368026A1 (en) * | 2015-10-27 | 2018-09-05 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors for the treatment of diabetic peripheral neuropathy |
WO2017108282A1 (en) | 2015-12-22 | 2017-06-29 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
US20190192521A1 (en) | 2016-08-15 | 2019-06-27 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors |
JP7282674B2 (ja) | 2016-10-28 | 2023-05-29 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤及びオーロラキナーゼ阻害剤を含む医薬品組み合わせならびにその使用方法 |
EP3532054A4 (en) | 2016-10-28 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLASE INHIBITOR AND EPOTHILON AND METHOD FOR USE THEREOF |
JP2019537580A (ja) | 2016-11-04 | 2019-12-26 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とbcl−2阻害剤とを含む医薬品配合物、及びそれらの使用方法 |
EP3544600A4 (en) | 2016-11-23 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF |
EP3544612A4 (en) | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
WO2018129533A1 (en) | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Llc | Selective histone deacetylase inhibitors for the treatment of human disease |
JP7237010B2 (ja) | 2017-01-10 | 2023-03-10 | シーストーン・ファーマスーティカルズ・(スージョウ)・カンパニー・リミテッド | Hdac6選択的阻害剤およびその製造方法と使用 |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
CA3059881A1 (en) | 2017-04-11 | 2018-10-18 | The General Hospital Corporation | Hdac6 inhibitors and imaging agents |
EP3424925A1 (en) | 2017-07-06 | 2019-01-09 | Universität Regensburg | Novel hdac6 inhibitors, with improved solubility and their uses |
IT201700086293A1 (it) | 2017-07-27 | 2019-01-27 | St Oncologico Veneto Iov Irccs | Inibitori della istone deacetilasi 6 per il trattamento della leucemia linfoblastica acuta a cellule t (t-all) e di altre neoplasie con elevata espressione di notch3 |
WO2019027054A1 (en) * | 2017-07-31 | 2019-02-07 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
EP3664828A1 (en) | 2017-08-10 | 2020-06-17 | Friedrich Miescher Institute for Biomedical Research | Hdac6 and protein aggregation |
US20190216751A1 (en) | 2017-11-15 | 2019-07-18 | California State University Northridge | Compositions and Methods for the Treatment and Prevention of Cancer |
WO2019110663A1 (en) | 2017-12-05 | 2019-06-13 | Oryzon Genomics, S.A. | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors |
US11407723B2 (en) | 2018-01-09 | 2022-08-09 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
KR102059027B1 (ko) | 2018-01-12 | 2019-12-24 | 주식회사 비엔에이치리서치 | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 |
WO2019169267A1 (en) | 2018-03-01 | 2019-09-06 | Reaction Biology Corp. | Quinoline and isoquinoline based hdac inhibitors and methods of use thereof |
US11155550B2 (en) | 2018-03-01 | 2021-10-26 | Reaction Biology Corporation | Histone deacetylase inhibitors and methods of use thereof |
US11045458B2 (en) | 2018-07-23 | 2021-06-29 | Wisconsin Alumni Research Foundation | Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them |
CA3156060A1 (en) | 2019-09-27 | 2021-04-01 | Takeda Pharmaceutical Company Limited | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS |
CA3156303A1 (en) | 2019-10-03 | 2021-04-08 | Tenaya Therapeutics, Inc. | 5-FLUORONICOTINAMIDE DERIVATIVES AND THEIR USES |
KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
-
2022
- 2022-05-04 CA CA3216768A patent/CA3216768A1/en active Pending
- 2022-05-04 AU AU2022270657A patent/AU2022270657A1/en active Pending
- 2022-05-04 TW TW111116861A patent/TW202308619A/zh unknown
- 2022-05-04 MX MX2023012875A patent/MX2023012875A/es unknown
- 2022-05-04 EP EP22731345.9A patent/EP4333841A1/en active Pending
- 2022-05-04 IL IL308152A patent/IL308152A/en unknown
- 2022-05-04 JP JP2023567974A patent/JP2024519499A/ja active Pending
- 2022-05-04 KR KR1020237038406A patent/KR20240016950A/ko unknown
- 2022-05-04 WO PCT/US2022/027725 patent/WO2022235842A1/en active Application Filing
-
2023
- 2023-07-27 US US18/360,752 patent/US20230381148A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022270657A1 (en) | 2023-11-16 |
KR20240016950A (ko) | 2024-02-06 |
CA3216768A1 (en) | 2022-11-10 |
IL308152A (en) | 2024-01-01 |
WO2022235842A1 (en) | 2022-11-10 |
US20230381148A1 (en) | 2023-11-30 |
EP4333841A1 (en) | 2024-03-13 |
TW202308619A (zh) | 2023-03-01 |
JP2024519499A (ja) | 2024-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
MX2022011804A (es) | Uso de agentes para el tratamiento de condiciones respiratorias. | |
MX2023012095A (es) | Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada. | |
BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
WO2008147482A3 (en) | Methods and compositions for improving immune responses | |
AR119158A1 (es) | Tratamientos de angioedema hereditario | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
NZ627181A (en) | Method of treating atrial fibrillation | |
MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
MX2020013163A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
Giraud et al. | The LUCAS 2 chest compression device is not always efficient: an echographic confirmation | |
AR119159A1 (es) | Tratamientos de angioedema | |
ZA202210079B (en) | Compositions and methods for treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases | |
MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
BR0112280A (pt) | Nova utilização para deferiprona | |
BR112023021131A2 (pt) | Tratamento de tremor essencial | |
WO2019139956A3 (en) | Prevention and treatment of organ fibrosis | |
WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
AR074108A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
WO2006020912A3 (en) | Treatments for congestive heart failure | |
MY200960A (en) | Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury |